Pembrolizumab trials for Metastatic Lung Non-Small Cell Carcinoma

All Pembrolizumab trials · All Metastatic Lung Non-Small Cell Carcinoma trials

Phase breakdown

Recruiting trials studying Pembrolizumab for Metastatic Lung Non-Small Cell Carcinoma

• A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
  NCT07619599 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
  NCT06731270 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
  NCT07017829 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations

Common questions

How many trials study Pembrolizumab for Metastatic Lung Non-Small Cell Carcinoma?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.